HIV integrase and the swan song of the CD4 T cells?

Jérôme Estaquier1,2*, John Zaunders3 and Mireille Laforge1

Abstract

T cell apoptosis represents one pathophysiological mechanism associated with AIDS. Herein, we discuss the recent report published by A. Cooper et al. in Nature (June 2013) regarding HIV viral DNA integration-mediated apoptosis.

Keywords: HIV, Apoptosis, DNA, p53, DNA-PK

Background

Over twenty years ago it was hypothesized that CD4+ T lymphocyte depletion during HIV infection resulted from apoptosis [1,2], and since then numerous research teams have strived to identify the associated cellular and molecular mechanisms. As early as 1991, studies by Drs. D. Richman [3] and A. Hovanessian [4] showed that the virus induces apoptosis in lymphoblastoid T cell lines or mitogen-activated primary CD4+ T cells in vitro. This programmed cell death is independent of caspase activation [5-10], the main effector proteases involved in apoptosis [11].

Main text

A paper recently published by A. Cooper et al. in Nature [12] suggests that integration of viral DNA is responsible for this apoptosis via activation of p53 by DNA-dependent protein kinase (DNA-PK), a protein kinase participating in DNA damage response. The authors show that apoptosis is only displayed by cells that do not express p24 antigen. An analysis of in vitro stimulated cells obtained from three HIV-infected individuals not receiving therapy suggested that the cells not expressing p24 antigen died in a proportion of 70 to >90%, but only 10 – 25% of these cells contained HIV DNA by qPCR. Furthermore, p24+ cells – representing 0.1-0.5% of CD4 T cells – died at a rate of 30~70%. This result implies that overall more than 90% of the CD4 T lymphocytes from HIV infected individuals underwent apoptosis in vitro, a proportion that seems to be incompatible with the in vivo status of these HIV-infected patients having CD4 cell counts up to 600 per mm³. The study also shows that blocking viral integration with raltegravir, an inhibitor of HIV integrase, decreased the occurrence of cell death not only in T/B lymphoblastoid cell line CEMX174, but also in primary CD4 T cells activated with PHA/IL-2. Likewise, a virus bearing a mutated integrase (D64V) caused less apoptosis. The authors propose that viral integration was responsible for cell death. Thus, lymphocytes would die before the virus gets a chance to replicate. Considering this, one has to wonder what advantage a pathogenic agent may gain from such a mechanism. Previous work by Dr. F. Bushman [13] had shown that it may be the accumulation of viral DNA and not its integration that could induce this apoptosis during activation of CD4+ T lymphocytes. This accumulation of viral DNA has also been proposed to induce the death of T cells in a human tonsil model [14] – described as early as the 1990s by Margolis’ group as supporting viral replication [15]. This process is accompanied by chronic inflammatory response that can be associated with caspase-1 activation, a caspase involved in pyroptotic cell death [16].

Cooper et al. furthermore propose that a phosphorylation of proteins p53 and H2AX accompanies this process via DNA-PK activation. Pharmacological inhibition of DNA-PK activation not only prevents phosphorylation of these two molecules, but cell death as well. The role of the DNA-PK pathway is largely studied in the context of double-strand break repair through non-homologous end joining (NHEJ). In 1999, Daniel and colleagues [17] reported that DNA-PK activity increases as a consequence of retroviral integration. The authors also showed that an
HIV-1–based virus vector induced death in scid pre-B cell lines. This death was proposed to be due to a defect in DNA-PK in these cell lines, resulting in a lack of DNA repair needed to complete the retroviral integration. Several groups subsequently showed that DNA damage sensors ATM, ATR, DNA-PK, and PARP-1 were, however, not required for efficient HIV-1 integration [18,19], and a protective role of DNA-PK was only observed against death induced by high levels of retrovirus integration. Thus, DNA-PK may exert a protective effect on the infected cells, a claim exactly opposite to that of Cooper and colleagues. Moreover, it has been reported that the activity of HIV-1 integrase stimulates an ATM-dependent DNA damage response, and that a deficiency of this kinase sensitizes cells to retrovirus-induced cell death [20]. Paradoxically, the inhibitor used in that study was KU55933, which was the same molecule utilized by Cooper and colleagues to show that ATM inhibition does not relieve cell death upon HIV infection. A possible explanation of such controversial results should be the difference of cells used in these studies, cell lines versus primary T cells.

Lastly, the authors show that inhibiting p53 activation with a pharmacological agent, pifithrin, also blocks CD4 T cell apoptosis. However, the nature of the cells expressing p53 and DNA-PK was not assessed by the authors, although implicitly they suggested p24– cells. On the contrary, several groups, including ours, have previously shown that phosphorylation of p53 and expression of target genes only occurred in cells replicating the virus (p24+) [21-23]. We have also recently shown that silencing p53 with interfering RNA reduces apoptosis [23] and increases viral replication in primary CD4 T cells. Therefore, we favour the hypothesis that p53 activation constitutes a stress-sensing mechanism, allowing auto-elimination of infected cells, and thus a host altruistic defence mechanism limiting viral dissemination. This programmed cell death is associated with lysosomal destabilization [10,23], which requires viral replication, since bystander cells – exposed to the virus, but not infected – do not display lysosomal destabilization.

Although increased activation of CD4 T cells during HIV-1 infection promotes viral production, the fact remains that the proportion of productively infected CD4 T cells in lymphoid tissue is very low, 0.25 - 1% or less of the cells that contain HIV DNA, which in turn represent about 10 - 20% of all CD4 T cells (reviewed in [24]). Much of this HIV DNA, at least in circulating memory CD4 T cells during untreated HIV infection, is in a labile unintegrated linear form or in episomal 2-LTR circles, [25]. After extended antiretroviral treatment of HIV-infected subjects, the cells containing integrated HIV DNA are long-lived [25,26]. The analysis of related simian immunodeficiency viruses (SIV), comparing those that are pathogenic for their hosts, such as SIVmac239 or SIVmac251, to the non-pathogenic SIVagm, SIVsm or SIVmnd, has shown that, despite a sustained viral replication in both pathogenic and non-pathogenic infections, only pathogenic models display an exacerbated apoptosis of CD4 T lymphocytes [27-30], beginning during primary infection [31-33]. Studies have shown that non-infected cells die mostly by apoptosis [34,35]. The level of apoptosis is a predictor of the rate of progression to AIDS and correlates with the innate immune response [36,37]. Furthermore, other work has shown in patients said to be discordant with respect to their immunovirological status - i.e. individuals for whom antiviral therapy is efficient, but in whom CD4 depletion continues – that there is an abnormal level of CD4+ T lymphocyte apoptosis [38]. Taken all together, it seems unlikely that integration of HIV DNA per se is responsible for the apoptosis observed in lymphoid tissues in vivo and clinically relevant CD4 depletion.

Considering the various non-human primate (NHP) models, it is noteworthy that the immune response of CD4 T lymphocytes of AGM monkeys or sooty mangabeys is extremely limited [29,39,40] and that their weakly activated central memory cells contain most of the viral DNA [41]. Several studies have indeed shown that chronic activation of the immune system may induce an activation-induced cell death (AICD)-type apoptosis via death receptors, particularly Fas and its ligand [32,42-48], with the latter being more weakly expressed in non-pathogenic infection models [49]. Furthermore, a role has been proposed for Trail and its death receptors, TRAIL-R1/R2, via type-1 interferons [50], although this work remains controversial [46,49,51,52]. Moreover, Trail has little influence on T lymphocyte homeostasis, as opposed to Fas, or the major part played by Bim, a pro-apoptotic member of the Bcl-2 family [53-55]. A role for Bim has been described, first in NHPs infected by SIV [46], but also in HIV patients [56]. Therefore, increased apoptosis could be due to activation, rather than infection of cells by HIV-1. However, addition of cyclosporine A, an inhibitor of T cell activation, to antiretroviral therapy (ART) does not provide apparent virologic or immunologic benefit [57].

Furthermore, the absence of co-signals by APCs [58] and the production of immunosuppressive cytokines, such as interleukin-10 or TGF-β, may trigger T cell apoptosis [43,59,60] involving Bim. It is noteworthy that adding exogenous factors, such as interleukins-2, -12 or -15, can prevent apoptosis of CD4 T lymphocytes ex vivo [44,61,62], via induction of anti-apoptotic cellular factors such as Bcl-2 or Bcl-x, antagonists of Bim. However, immunotherapy based on IL-2 did not yield any benefit during the chronic phase of either HIV or SIV-infections [63,64].

IL-7 is the most important anti-apoptotic exogenous signal for T cell survival in vivo. We have shown directly
that highly activated CD8 T cells in subjects during primary HIV-1 infection have reduced IL-7 receptor and reduced Bcl-2 and rapidly undergo apoptosis in vitro, unless cultured with the common gamma-chain cytokines IL-2 or IL-15 [65]. However, IL-7 signalling may additionally enhance integration of HIV-1 into the genome of target CD4 T cells [66] as well as re-activation of productive infection from latently infected cells [67]. Furthermore, its impact on CD4 T death seems to depend on the duration of exposure to this cytokine or on production of accessory cytokines. It indeed displays no discernible effect on purified CD4 T lymphocytes [44], whereas added to PBMCs it prevents apoptosis after 4 days of culture [68].

Increased IL-7 levels in progressive HIV-1 infection may also increase the expression of the coreceptor CCRX4, resulting in a greater risk of emergence of an X4-using viral strain [69], and in turn IL-7 may prove to be more deleterious and pro-apoptogenic with these X4 viral strains, as it causes an increase of Fas [70-72]. Not only does the interaction between the viral envelope and the CD4 molecule prime the cells to undergo apoptosis [73-77], but interaction with viral coreceptors CCR5 and CXCR4 may also induce apoptosis and enhance Fas-mediated cell death independently of immune activation [32,78-80]. Given this possible role of co-receptors in initiating apoptosis, does Maraviroc, a CCR5 inhibitor, have an enhanced role in vivo in inhibiting CD4 T cell death?

Considering NHP models, a simple question must be asked - WHY do these viruses, albeit “cytolytic” after in vitro stimulation, not cause in their hosts a very rapid depletion of CD4 T lymphocytes, in all models of infection? In fact, based on the suggestion by Cooper et al. that every cell integrating HIV DNA automatically dies, non-pathogenic SIV infection in NHP should not be possible. Moreover, what would be the possible advantage for the virus to activate and deplete the immune system if this leads to a very rapid death of its host? It should be remembered that HIV-1 infection is a recent zoonosis, to which HIV-1 has presumably not yet completely adapted. Clearly the activation of the immune system that results from HIV-1 infection may increase target cells for productive infection in the short term, but may also relatively rapidly lead to the demise of the host and presumably reduce overall the chance of transmission (notwithstanding the size of the HIV-1 pandemic). Conversely, does a non-pathogenic SIV in its natural host intentionally limit lymphocyte activation more than the strong activation of a pathogenic strain of SIV or HIV? Is the virus trying to minimize the CD4 response, to render it relatively anergic, in order to facilitate its own dissemination? Likewise, does the localization of the virus into sites where the immune response is tightly controlled, such as the intestine, represent an evasion strategy, a way to hide in sanctuaries characterized by weak activation? This could account for viral persistence in HIV-infected patients in spite of several years of highly-active therapy. Therefore, like Orpheus do non-pathogenic viruses render the cells resistant to the song of death.

Conclusions
In conclusion, this new study from Cooper et al. proposes an apoptosis molecular mechanism linked to viral integration associated with the activation of p53 and DNA-PK. However, this concept is difficult to reconcile with known in vivo events, and, furthermore, an eventual therapeutic strategy aimed at blocking p53 or DNA-PK could be highly risky, by promoting either viral replication or cancer. Due to the complexity of the biochemical apoptotic pathways described leading to CD4 cell death, inhibiting this process in vivo presents a real challenge.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
EJ, JZ, and LM wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgement
This work was funded by grants to JE from the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS). JE thanks the Canada Research Chair program for financial assistance.

Author details
1CNRS FRE 3235, Université Paris Descartes, Paris, France. 2Université Laval, Centre de Recherche en Infectiologie, Quebec, Canada. 3St Vincent’s Centre for Applied Medical Research, St Vincent’s Hospital, Darlinghurst, NSW, Australia.

Received: 12 August 2013 Accepted: 6 November 2013 Published: 9 December 2013

References
1. Ameisen JC, Estaquier J, Idziorek T: From AIDS to parasite infection: pathogen-mediated subversion of programmed cell death as a mechanism for immune dysregulation. Immunol Rev 1994, 142:9–51.
2. Ameisen JC, Capron A: Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis. Immunol Today 1991, 12:102–105.
3. Feria C, Kornbluth RS, Pausa CD, Richman DD, Carson DA: Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. J Clin Invest 1991, 87:1710–1715.
4. Laurent-Crawford AG, Kurtz B, Muller S, Riviere Y, Rey-Cuillé MA, Bechet JM, Montagnier L, Hovanessian AG: The cytopathic effect of HIV is associated with apoptosis. Virology 1991, 183:829–839.
5. Gandhi RT, Chen BK, Straus SE, Dale JK, Lennon MJ, Baltimore D: HIV-1 directly kills CD4+ T cells by a Fas-independent mechanism. J Exp Med 1998, 187:1113–1122.
6. Pett F, Arnout D, Leleveo JD, Moutouh-de Parseval L, Hance AJ, Schneider P, Corbel J, Ameisen JC, Estaquier J: Protractive HIV-1 infection of primary CD4+ T cells induces mitochondrial membrane permeabilisation leading to a caspase-independent cell death. J Biol Chem 2002, 277:1477–1487.
7. Lennon MJ, Angleman SB, Bourne R, Dimas J, Dusailly MG, Graubard MB, Hornung F, Sellke MC, Speirs CK, Trager M, Orenstein JD, Bolton DL: Pyroptosis of human monocyte-derived macrophages and is induced by the HIV-1 envelope transmembrane glycoprotein gp120. J Biol Chem 2003, 278:2492–2497.
8. Moutouh L, Estaquier J, Richman DD, Corbel J: Molecular and cellular analysis of human immunodeficiency virus-induced apoptosis in
lymphoblastoid T-cell-line-expressing wild-type and mutated CD4 receptors. J Virol 1998, 72:8061–8072.

9. Leilleve JD, Petit F, Perrin L, Mannamo F, Arnould D, Ameisen JC, Corbel J, Gervais J, Estaquij J. The density of coreceptors at the surface of CD4+/T cells contributes to the extent of human immunodeficiency virus type 1 viral replication-mediated T cell death. AIDS Res Hum Retroviruses 2004, 20:1230–1234.

10. Laforge M, Petit F, Estaquij J, Senik A: Commitment to apoptosis in CD4 (+) T lymphocytes productively infected with human immunodeficiency virus type 1 is initiated by lysosomal membrane permeabilization, itself induced by the isolated expression of the viral protein Nef. J Virol 2007, 81:11426–11440.

11. Thornberry NA, Lazebnik Y: Caspases: enemies within. Science 1998, 281:1312–1316.

12. Cooper A, Garcia M, Petrovas C, Yamamoto T, Koup RA, Nabel GJ: HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. Nature 2013, 498:376–379.

13. Li L, Oliver JM, Yodere KE, Mitchell RS, Butler SL, Lieber M, Martin SL, Thornberry NA, Lazebnik Y: DNA-PKcs, and PARP-1 are dispensable for human immunodeficiency virus type 1 integration. J Virol 1999, 73:344–347.

14. Doitsh G, Cavrois M, Lassen KG, Zepeda O, Yang Z, Santiago ML, Hebbeler AM, Petit F, Corbeil J, Lelievre JD, Moutouh-de Parseval L, Pinon G, Green DR, Ariumi Y, Turelli P, Masutani M, Trono D: Early divergence of CD4(+) T lymphocyte apoptosis between pathogenic and nonpathogenic simian immunodeficiency virus infections of nonhuman primates. J Virol 2008, 82:1175–1184.

15. Moncejou V, Estaquij J, Fevrier M, Cumont MC, Riviere J, Aubertin AM, Ameisen JC, Hurtel B: Extensive apoptosis in lymphoid organs during primary SIV infection predicts rapid progression towards AIDS. AIDS 2003, 17:585–1596.

16. Volet L, Moncejou V, Petit F, Ho Tsong Fang R, Cumont MC, Hurtel B, Estaquij J: Death of CD4+ T cells from lymph nodes during primary SIVmac251 infection predicts the rate of AIDS progression. J Immunol 2006, 177:6685–6694.

17. Cumont MC, Diop O, Vasilin B, Elbim C, Volet L, Moncejou V, Lay S, Silvestri G, Le Grand R, Muller-Trutwin M, Hurtel B, Estaquij J. Early divergence of CD4(+) T lymphocytes apoptosis between pathogenic and nonpathogenic simian immunodeficiency virus infections of nonhuman primates. J Virol 2008, 82:1175–1184.

18. Finkel TH, Tudor-Williams G, Band A, Cotton MF, Curiel T, Monks C, Baba TW, Ruprecht RM, Kupfer A: Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV-1- and SIV-infected lymph nodes [see comments]. Nat Med 1998, 4:129–134.

19. Li L, Duan L, Estes JD, Ma ZM, Rouke T, Wang J, Reily C, Carls J, Miller CJ, Haase AT: Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005, 434:1148–1152.

20. Campillo-Gimenez L, Lafarge M, May F, Brussel A, Cumont MC, Moncejou V, Diop O, Levy T, Hurtel B, Zaunders J, Corbel J, Elbim C, Estaquij J: Nonpathogenesis of simian immunodeficiency virus infection is associated with reduced inflammation and recruitment of plasmacytoid dendritic cells to lymph nodes, not to lack of an interferon type 1 response, during the acute phase. J Virol 2010, 84:1838–1846.

21. Campillo-Gimenez L, Cumont MC, Fay M, Kared H, Moncejou V, Diop O, Muller-Trutwin M, Hurtel B, Levy T, Zaunders J, Dy M, Leite-de-Moraes MC, Elbim C, Estaquij J: AIDS progression is associated with the emergence of IL-17-producing cells early after simian immunodeficiency virus infection. J Immunol 2010, 184:984–992.

22. Bovenen O, Fialaunet R, Rolf F, Elbim C, Estaquij J, Pedron B, Duval X, Dereuddre-Bosquet N, Clayette P, Sterkers G, Simon A, Ameisen JC, Leport C: Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis 2005, 191:1670–1679.

23. Willeing F, Foks TM, Lauro S, Powell JD, Sundstrom JB, Mayne A, Ansari AA: Immunological and virological studies of natural SIV infection of disease-resistant nonhuman primates. Immunol Lett 1996, 5159–68.

24. Chakraborti LA, Luckay A, Marx PA: A divergent simian immunodeficiency virus from sooty mangabeys with an atypical Tat-TAR structure. AIDS Res Hum Retroviruses 2001, 17:1155–1165.

25. Paaridin M, Cevski B, Reyes-Aviles E, Micci L, Ortíz AM, Chahroudi A, Vinton C, Gordon SN, Bosing SE, Francella N, Hallberg PL, Cramer E, Schuhl T, Chan ML, Riddick NE, Collman RG, Apeireti C, Pandia I, Else J, Munch J, Kirchoff F, Davenport MP, Brenchley JM, Silvestri G: Low levels of SIV infection in sooty mangabey central memory CD4(+) T cells are associated with limited CCR5 expression. Nat Med 2011, 17:830–836.

26. Katolik PD, Wunderlich ES, Smith CA, Herzenberg LA: Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J Exp Med 1995, 181:2029–2036.

27. Estaquij J, Idziorek T, Zou W, Emile O, Farber CM, Bourez JM, Ameisen JC: T helper type 1/17 helper T cells, 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus- infected persons. J Exp Med 1995, 182:1759–1767.

28. Estaquij J, Tanaka M, Suda T, Nagata S, Golstein P, Ameisen JC: Fas-mediated apoptosis of CD4+ and CD8+ T cells from human immunodeficiency virus-infected persons: differential in vitro preventive effect of cytokines and protease antagonists. Blood 1996, 87:4955–4966.
45. Baumler JB, Bohler T, Herr I, Benner A, Kramer PH, Debatin KM: Activation of the CD95 (APO-1/Fas) system in T cells from human immunodeficiency virus type-1-infected children. Blood 1996, 88:1741–1746.

46. Amrou D, Petit F, Lelievre JD, Lecossier D, Hance A, Monceaux V, Ho Tsong Fang R, Hurtle B, Ameisen JC, Estaquier J: Caspase-dependent and independent T-cell death pathways in pathogenic simian immunodeficiency virus infection: relationship to disease progression. J Infect Dis 2003, 187:1240–1252.

47. Badley AD, Dockrell DH, Algeciras A, Ziesmer S, Landay A, Lederman MM, Connick E, Kessler H, Kuritzkes D, Lynch DH, Roche P, Yagita H, Paya CV: In vivo analysis of Fas/Fasl interactions in HIV-infected patients. J Clin Invest 1998, 102:79–87.

48. Algeciras A, Dockrell DH, Lynch DH, Paya CV: CD4 regulates susceptibility to Fas ligand- and tumor necrosis factor-mediated apoptosis. J Exp Med 1998, 187:711–720.

49. Lecossier D, Bouchonnet F, Schneider P, Clavel F, Hance AJ: Transcription factor FOXO3a controls the persistence of memory CD4(+), CD8(+) T cells during HIV infection. Nat Med 2003, 9:158–165.

50. Herbeuval JP, Boasso A, Grivel JC, Hardy AW, Anderson SA, Dolan MJ, Zaunders J, Elbim C, Estaquier J: IL-7 enhances immune functions during HIV infection: regulation by interleukin (IL)-2, IL-15, and Bcl-2. J Infect Dis 2003, 187:1735–1747.

51. Lecossier D, Bouchonnet F, Schneider P, Clavel F, Hance AJ: Effects on T-cell phenotype. J Virol 2002, 76:13077–13082.

52. Chehimi J, Papasavvas E, Tomescu C, Gekonge B, Abdulhaqq S, Raymond A, Locci L, Kelleher A, Cooper DA, Smith DE, Grey P, Estaquier J, Little S, Richman DD, Corbel J: Polyclonal proliferation and apoptosis of CCR5+ T lymphocytes during primary human immunodeficiency virus type 1 infection: regulation by interleukin (IL)-2, IL-15, and Bcl-2. J Infect Dis 2003, 187:1735–1747.

53. Weant AE, Michalek RD, Khan IU, Holbrook BC, Willingham MC, Grayson JM: Combined deficiency of proapoptotic regulators Bim and Fas function concurrently to control autoimmunity and CD4+ T cell contraction. Immunity 2008, 28:218–230.

54. Warr TL, Scatizzi JC, Siddiqui AM, Haines GK 3rd, Wu T, Li QZ, Davis LS, Hutcheson J, Paya CV: Exogenous IL-7 induces Fas-mediated human neuronal apoptosis: potential effects during human immunodeficiency virus type 1 infection. J Neurovirol 2005, 11:319–328.

55. Hughes PD, Belz GT, Fortner KA, Budd RC, Strasser A, Bouillet P: Apoptosis regulators Fas and Bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity 2008, 28:197–205.

56. van de Wiel M, van der Broek M, Delaporte E, Montaner LJ, Krammer PH: Ligand-induced apoptosis in resting primary T lymphocytes. Cell Death Differ 2003, 10:2638–2646.

57. Carvalho MM, Carvalho PN, Godinho S, Ruiz-Antolín A, Miró JM, Montaner LJ: Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood 2005, 105:2458–2464.

58. Amrou D, Petit F, Lelievre JD, Ameisen JC, Estaquier J: IL-2 immunotherapy in chronically SIV-infected rhesus macaques. Virol J 2012, 9:220.

59. Montaño-Ahumada J, Montaño-Montoya T, Bai N, Vazquez-Domínguez D, Richman DD, Corbel J: Interleukin-7 induces HIV type 1 RNA to −X switched. Blood 2011, 117:2073–2074.

60. Oyaizu N, McCloskey TW, Than S, Hu R, Kalyanaraman VS, Pahwa S: Accelerated apoptosis in peripheral blood mononuclear cells (PBMCs) from human immunodeficiency virus type-1 infected patients and in CD4 cross-linked PBMCs from normal individuals. Blood 1993, 82:3392–3400.

61. Oyaizu N, McCloskey TW, Than S, Hu R, Kalyanaraman VS, Pahwa S: Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-gamma and tumor necrosis factor-alpha secretion. Blood 1994, 84:2622–2631.

62. Eiser MT, Bress JJr, Suryanarayana K, Chentoufi E, Herr DJ, Carrington M, Arthur LO, Dockrell JD: Partial activation and induction of apoptosis in CD4 (+) and CD8(+)-T lymphocytes by conformationally authentic noninfectious human immunodeficiency virus type 1. J Virol 2001, 75:1152–1164.

63. Bernst C, Motts B, Angermüller S, Gierschik P, Kramer PH: CXCR4 and CD4 mediate a rapid CD95-independent cell death in CD4(+)-T cells. Proc Natl Acad Sci USA 1998, 95:12556–12561.

64. Amrou D, Petit F, Corbel J, Paya CV: Potential role for IL-7 in Fas-mediated T cell apoptosis during HIV infection. J Immunol 2007, 178:5340–5350.

65. Estequier, et al.: HIV Integrase and the swan song of the CD4 T cells? Retrovirology 2013 10:149.